Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Professor Sara Linse presents new data on protein interactions in Alzheimer’s disease using the Fluidity One-W at FEBS 2019

Fluidic Analytics’ diffusional sizing technology has been influential in a recent study that investigates protein binding and self-assembly in Alzheimer’s disease.

From Fluidic Analytics 8 Feb 2023

Researchers develop a new method to design peptide antibiotics

Hokkaido University researchers have developed a novel method to design and develop peptide antibiotics in large numbers, which will prove critical to controlling antibiotic resistance.

7 Feb 2023

Mucoactive drugs block SARS-CoV-2 infection

Researchers evaluate the effects of mucociliary active molecules on SARS-CoV-2 infection in vitro.

7 Feb 2023

USC researchers identify two promising avenues for developing new ALS treatments

Each year in the U.S., 5,000 patients receive a diagnosis of ALS, an incurable neurodegenerative disease that will likely kill them within two to five years.

7 Feb 2023

Targeting a single enzyme can kill prostate cancer cells

For the first time, researchers have discovered that prostate cancer can be killed by targeting a single enzyme, called PI5P4Kα.

3 Feb 2023

Oncodesign Services looks to the future

As Oncodesign evolves into Oncodesign Services and begins its journey as an independent business, CEO Fabrice Viviani explains his hopes and plans for the company’s future.

From Oncodesign Services 3 Feb 2023

ERES IV acquires a majority stake in Oncodesign Services

Oncodesign Services, a leading Contract Research Organization (CRO) specializing in drug discovery and preclinical services in oncology and immuno-inflammation, and Elyan Partners announce the completion of the acquisition of a majority stake in Oncodesign Services by ERES IV, representing 61.58% of its share capital, from its main shareholders, including Mr. Philippe Genne, Founder of Oncodesign Services, as well as certain key shareholders and several managers and minority shareholders, following the entry into exclusive negotiations on June 30, 2022.

From Oncodesign Services 3 Feb 2023

CuSTOM; Creating a healthier society by accelerating the translation of organoid technology

In this interview, we speak to Magdalena Kasendra at the CuSTOM Accelerator, about the organoid technology and how it has the power the revolutionize healthcare.

From Society for Laboratory Automation and Screening (SLAS) 1 Feb 2023

A high-throughput screening assay for small molecule inhibitors of the antigen aminopeptidase ERAP1

The January 2023 issue of SLAS Discovery contains a collection of four full-length articles and one technical brief covering cancer research, high-throughput screening (HTS) assay development and other drug discovery exploration.

27 Jan 2023

bit.bio partners with Automata to automate a key aspect of its production of iPSC derived human cells

...

From Automata 26 Jan 2023

Aston University scientists team up with Isterian Biotech to develop novel drugs to treat fibrotic diseases

Aston University scientists are working with start-up company, Isterian Biotech, part of Cambrian BioPharma, to develop novel drugs to treat fibrotic diseases such as lung disease.

23 Jan 2023

Ubiquigent collaborates with University of Glasgow on translational structural biology to accelerate drug discovery within the (de)ubiquitylation field

Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced it is supporting a Master’s student at the University of Glasgow (UoG) to undertake a research project on USP30, a DUB implicated in neurodegenerative, renal, and cardiovascular diseases.

From Ubiquigent Limited 23 Jan 2023